Exhibitor

Based on its 25 years of experience, EPO is offering customized and comprehensive preclinical oncology and immuno-oncology services for the development of novel anti-cancer drugs. Our portfolio includes more than 600 well characterized PDX models of about 17 cancer entities (solid cancers, leukemia), CDX as well as syngeneic tumor models. EPO has long term experience in the establishment of humanized models and has been running studies in these for over a decade.